Quick Answer
Calidi Biotherapeutics, Inc. reported Operating Income of -$20.24 million for fiscal year 2025.
Calidi Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$20.24M | +7.1% |
| 2024 | -$21.78M | +24.9% |
| 2023 | -$28.99M | -25.4% |
| 2022 | -$23.13M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.05M | +3.4% | +10.9% |
| June 30, 2025 | -$5.66M | +1.9% | -11.9% |
| March 31, 2025 | -$5.06M | +25.0% | +3.1% |
| September 30, 2024 | -$5.23M | +27.6% | +9.5% |
| June 30, 2024 | -$5.77M | +11.7% | +14.5% |
| March 31, 2024 | -$6.75M | -24.7% | +6.5% |
| September 30, 2023 | -$7.22M | -3.4% | -10.5% |
| June 30, 2023 | -$6.54M | -1707.7% | -20.7% |
- Calidi Biotherapeutics, Inc. showed an increase of +7.1% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Calidi Biotherapeutics, Inc.’s operating income has grown by 12.5% (from -$23.13 million to -$20.24 million).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: